Evaluation of Drug-Drug Interactions via Inhibition of Hydrolases by Orlistat, an Anti-Obesity Drug
Drug Metabolism and Disposition · 2023
DOI: 10.1124/dmd.123.001266 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2023. Verfasst von Keiya Hirosawa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University (K.H., T.F., Ma.N., Mi.N.) and WPI Nano Life Science Institut…. Hauptthemen laut MEDLINE: Hydrolases, Anti-Obesity Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University (K.H., T.F., Ma.N., Mi.N.) and WPI Nano Life Science Institute, Kanazawa, Japan (T.F., Ma.N., Mi.N.).
- Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University (K.H., T.F., Ma.N., Mi.N.) and WPI Nano Life Science Institute, Kanazawa, Japan (T.F., Ma.N., Mi.N.) tatsuki@p.kanazawa-u.ac.jp.
Zitieren
APA
Hirosawa, K., Fukami, T., Nakano, M., & Nakajima, M. (2023). Evaluation of Drug-Drug Interactions via Inhibition of Hydrolases by Orlistat, an Anti-Obesity Drug. Drug Metabolism and Disposition. https://doi.org/10.1124/dmd.123.001266
Vancouver
Hirosawa K, Fukami T, Nakano M, Nakajima M. Evaluation of Drug-Drug Interactions via Inhibition of Hydrolases by Orlistat, an Anti-Obesity Drug. Drug Metabolism and Disposition. 2023. doi:10.1124/dmd.123.001266
BibTeX
@article{Hirosawa2023,
author = {Hirosawa, Keiya and Fukami, Tatsuki and Nakano, Masataka and Nakajima, Miki},
title = {Evaluation of Drug-Drug Interactions via Inhibition of Hydrolases by Orlistat, an Anti-Obesity Drug},
journal = {Drug Metabolism and Disposition},
year = {2023},
doi = {10.1124/dmd.123.001266}
}
EUVIMED